BiotechTube

MRA(Tocilizumab)

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Polyarticular Juvenile Idiopathic Arthritis

Conditions

Polyarticular Juvenile Idiopathic Arthritis

Trial Timeline

Feb 1, 2005 → Jun 1, 2009

NCT ID
NCT00144625

About MRA(Tocilizumab)

MRA(Tocilizumab) is a phase 3 stage product being developed by Chugai Pharmaceutical for Polyarticular Juvenile Idiopathic Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT00144625. Target conditions include Polyarticular Juvenile Idiopathic Arthritis.

What happened to similar drugs?

0 of 2 similar drugs in Polyarticular Juvenile Idiopathic Arthritis were approved

Approved (0) Terminated (0) Active (2)
🔄AbataceptBristol Myers SquibbPhase 3
🔄Certolizumab Pegol (CZP) + Certolizumab Pegol (CZP)UCBPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (9)

NCT IDPhaseStatus
NCT00380601Phase 3Completed
NCT00144586Phase 3Completed
NCT00144625Phase 3Completed
NCT00144560Pre-clinicalCompleted
NCT00144573Pre-clinicalCompleted
NCT00144664Phase 3Completed
NCT00144612Phase 3Completed
NCT00144547Phase 3Completed
NCT00144651Phase 2Completed

Competing Products

2 competing products in Polyarticular Juvenile Idiopathic Arthritis

See all competitors
ProductCompanyStageHype Score
AbataceptBristol Myers SquibbPhase 3
40
Certolizumab Pegol (CZP) + Certolizumab Pegol (CZP)UCBPhase 3
40